ArticleNPJ vaccines2021

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents.

Susanne Rauch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.